Dave Joffe R.Ph., FACA & Caren Spinner
Dave Joffe R.Ph., FACA
Dave Joffe - is a graduate of University of Kentucky College of Pharmacy. He has practiced in the Tampa Bay area since 1986 and got involved in Diabetes Care in 1994. He is a 1994 graduate of the Eli Lilly Diabetes Program as a Diabetes Education Specialist. In 1997 he completed his NIPCO Certification Program as a Diabetes Outcome Manger. He completed the AADE Pharmaceutical Care Program for Diabetes Educators in 1999 and the University Minnesota Patient Care Program that same year. Also in 1999 he attended the LifeScan Pharmacy Partners in Diabetes Care Program. He attended the 2002 University South Florida, CDE Certification Course and 2002, AADE Advanced Practice Diabetes Course before sitting for the National Certification Board CDE exam in Tampa in October of 2002. Dave earned the designation of CDE in October of 2002. He is a certified CGMS (continuous glucose monitoring system) provider and is on the speakers bureaus for TheraSense, Novo, HDI, Pfizer, Aventis, Bayer and BMS. Dave is Editor In Chief of DiabetesInControl Newsletter/ Ezine and Website.
Caren Spinner - In 2001, after 18 years in senior level positions in pharmaceutical and medical communications companies, Ms. Spinner became an independent consultant specializing in the areas pharmaceutical and biotechnology. Her experience covers everything from promotional concept development, marketing plans, strategic recommendations to developing and writing CME/CE. Her most recent focus has been the development of patient education programs, sales training and managed care marketing programs. The following disclosures were made: Ms. Spinner has no financial interest nor does she own stock in any company or product mentioned.
All faculty participating in the continuing pharmacy education activities sponsored by RxSchool are expected to disclose to participants any real or apparent conflicts of interest related to the content of their presentations. They are also expected to disclose any investigational or unlabeled uses of products discussed.
To give the Pharmacist a greater understanding of the Epidemiology and Prevalance of Cardiovascular Disease and the role that cholesterol plays.
Upon completion of this program, the participant will be able to:
- Discuss the general physiological conditions contributing to cardiovascular disease and their relationship to hyperlipidemia.
- Discuss the significance of hyperlipidemia as a risk factor for CV disease.
- Understand the recommendations of the NCEP (the National Cholesterol Education Program) Adult Treatment Panel III and communicate appropriate NCEP goals to the patient.
- Discuss the importance of regular cholesterol monitoring as a means of improving therapeutic outcomes in patients with CV disease.
- Describe how and why the pharmacist can be a significant contributor to CV patient compliance through regular cholesterol monitoring.
- Address the various methods that pharmacists can utilize to improve adherence and optimize clinical outcomes for patients with hyperlipidemia (medication counseling, recommendations for monitoring, raising patient awareness of using home monitoring devices, etc.).
- Act as a source of information and motivation to reinforce adherence among patients with hyperlipidemia.
CV Disease and Cholesterol
- Epidemiology, Prevalence
- Pathophysiology of CV disease
- The role of cholesterol in the pathophysiology of CV disease
- Understanding the Lipid Panel
- Review of relevant clinical literature
- Pharmacist Participation
Approved for Pharmacists and Pharmacy Technicians